195 related articles for article (PubMed ID: 2556074)
1. Synergistic therapy by acyclovir and A1110U for mice orofacially infected with herpes simplex viruses.
Ellis MN; Lobe DC; Spector T
Antimicrob Agents Chemother; 1989 Oct; 33(10):1691-6. PubMed ID: 2556074
[TBL] [Abstract][Full Text] [Related]
2. Synergistic topical therapy by acyclovir and A1110U for herpes simplex virus induced zosteriform rash in mice.
Lobe DC; Spector T; Ellis MN
Antiviral Res; 1991 Feb; 15(2):87-100. PubMed ID: 1650166
[TBL] [Abstract][Full Text] [Related]
3. Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.
Spector T; Lobe DC; Ellis MN; Blumenkopf TA; Szczech GM
Antimicrob Agents Chemother; 1992 May; 36(5):934-7. PubMed ID: 1324641
[TBL] [Abstract][Full Text] [Related]
4. Potential for combined therapy with 348U87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection.
Safrin S; Schacker T; Delehanty J; Hill E; Corey L
J Med Virol; 1993; Suppl 1():146-9. PubMed ID: 8245882
[TBL] [Abstract][Full Text] [Related]
5. Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir.
Safrin S; Schacker T; Delehanty J; Hill E; Corey L
Antimicrob Agents Chemother; 1993 May; 37(5):975-9. PubMed ID: 8390815
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.
Duan J; Liuzzi M; Paris W; Lambert M; Lawetz C; Moss N; Jaramillo J; Gauthier J; Déziel R; Cordingley MG
Antimicrob Agents Chemother; 1998 Jul; 42(7):1629-35. PubMed ID: 9660995
[TBL] [Abstract][Full Text] [Related]
7. Novel animal model for evaluating topical efficacy of antiviral agents: flux versus efficacy correlations in the acyclovir treatment of cutaneous herpes simplex virus type 1 (HSV-1) infections in hairless mice.
Lee PH; Su MH; Kern ER; Higuchi WI
Pharm Res; 1992 Aug; 9(8):979-89. PubMed ID: 1329068
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir.
Collins P; Ellis MN
J Med Virol; 1993; Suppl 1():58-66. PubMed ID: 8245894
[TBL] [Abstract][Full Text] [Related]
9. 2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir.
Spector T; Harrington JA; Morrison RW; Lambe CU; Nelson DJ; Averett DR; Biron K; Furman PA
Proc Natl Acad Sci U S A; 1989 Feb; 86(3):1051-5. PubMed ID: 2536930
[TBL] [Abstract][Full Text] [Related]
10. Influence of the treatment protocol upon the in vivo efficacy of cidofovir (HPMPC) and of acyclovir (ACV) formulations in topical treatment of cutaneous HSV-1 infection in hairless mice.
Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; DeClercq E; El-Shattawy HH
J Pharm Sci; 1999 May; 88(5):530-4. PubMed ID: 10229644
[TBL] [Abstract][Full Text] [Related]
11. Effect of Azone upon the in vivo antiviral efficacy of cidofovir or acyclovir topical formulations in treatment/prevention of cutaneous HSV-1 infections and its correlation with skin target site free drug concentration in hairless mice.
Afouna MI; Fincher TK; Zaghloul AA; Reddy IK
Int J Pharm; 2003 Mar; 253(1-2):159-68. PubMed ID: 12593946
[TBL] [Abstract][Full Text] [Related]
12. Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2.
Sauerbrei A; Bohn K; Heim A; Hofmann J; Weissbrich B; Schnitzler P; Hoffmann D; Zell R; Jahn G; Wutzler P; Hamprecht K
Antivir Ther; 2011; 16(8):1297-308. PubMed ID: 22155911
[TBL] [Abstract][Full Text] [Related]
13. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo.
Neyts J; Andrei G; De Clercq E
Antimicrob Agents Chemother; 1998 Feb; 42(2):216-22. PubMed ID: 9527762
[TBL] [Abstract][Full Text] [Related]
14. Characterization of latent infections in mice inoculated with herpes simplex virus which is clinically resistant to acyclovir.
Field HJ; Lay E
Antiviral Res; 1984 Apr; 4(1-2):43-52. PubMed ID: 6331304
[TBL] [Abstract][Full Text] [Related]
15. Pathogenicity and response to topical antiviral therapy in a murine model of acyclovir-sensitive and acyclovir-resistant herpes simplex viruses isolated from the same patient.
Lebel A; Boivin G
J Clin Virol; 2006 Sep; 37(1):34-7. PubMed ID: 16781887
[TBL] [Abstract][Full Text] [Related]
16. Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease.
Kristofferson A; Ericson AC; Sohl-Akerlund A; Datema R
J Gen Virol; 1988 Jun; 69 ( Pt 6)():1157-66. PubMed ID: 2838569
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice.
De Clercq E; Holý A
Antimicrob Agents Chemother; 1991 Apr; 35(4):701-6. PubMed ID: 2069375
[TBL] [Abstract][Full Text] [Related]
18. Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.
Duan J; Liuzzi M; Paris W; Liard F; Browne A; Dansereau N; Simoneau B; Faucher AM; Cordingley MG
Antimicrob Agents Chemother; 2003 Jun; 47(6):1798-804. PubMed ID: 12760851
[TBL] [Abstract][Full Text] [Related]
19. An acyclovir-resistant strain of herpes simplex virus type 2 which is highly virulent for mice.
Sakuma S; Yamamoto M; Kumano Y; Mori R
Arch Virol; 1988; 101(3-4):169-82. PubMed ID: 2845890
[TBL] [Abstract][Full Text] [Related]
20. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals.
Boyd MR; Bacon TH; Sutton D
Antimicrob Agents Chemother; 1988 Mar; 32(3):358-63. PubMed ID: 3364954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
